Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective - 09/08/11
Seattle, Washington, and Dallas, Texas
Abstract |
Psoriasis and psoriatic arthritis are inflammatory immune-mediated skin and joint conditions with major impacts on patients’ health-related quality of life (HRQOL). Physical manifestations include unsightly, scaly, pruritic plaques and inflamed joints for patients with psoriatic arthritis. These symptoms can severely impair physical functioning and occupational capability and negatively affect psychosocial domains. Consequently, patients often experience feelings of embarrassment, helplessness, and depression. Recent therapies, including the biologics, have been shown to improve not only the physical signs and symptoms of these conditions, but also patients’ HRQOL. To accurately assess these improvements, standardized and validated instruments are needed. However, there are currently a limited number of feasible and validated tools available in dermatology for measuring HRQOL and function. Valuable insights can be acquired from the rheumatology field, and refinement of existing outcome measures through a cooperative and consensus building process between dermatologists and rheumatologists will lead to standardization of assessment tools in the years ahead.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AIMS, DLQI, DQOLS, GHQ, HAQ, HRQOL, KMPI, NHP, NPF, OMERACT, PASI, PDI, PLSI, PQOL-12, PsA, PsAQOL, RA, SF-36, SIP, SPI, TNF
Plan
Funding sources: Supported by Amgen Inc and Wyeth. Disclosure: Dr Mease has received research support from and is a consultant and/or lecturer for Abbott Laboratories, Amgen Inc, Aventis, Biogen/Idec, Centocor Inc, Genentech Inc, Merck, Novartis, Pfizer, and Wyeth. Dr Menter has received research support from and is a consultant and/or a lecturer for Abbott Laboratories, Allergan Inc, Allermed, Amgen Inc, Astralis Inc, Berlex Inc, Biogen/Idec, Centocor Inc, Collagenex Pharmaceuticals, Connetics Corporation, Dermik Laboratories, Doak Dermatologics, Dow, Ferndale Laboratories Inc, Fujisawa Healthcare Inc, Galderma, Genentech Inc, GlaxoSmithKline, Ligand Pharmaceuticals, Medicis, MedImmune Inc, Novartis Pharmaceuticals, Otsuka Pharmaceuticals Inc, Serono, Synta Pharma, Thermosurgery, 3M Pharmaceuticals, and XOMA. |
Vol 54 - N° 4
P. 685-704 - avril 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?